Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

Event · Earnings
Also in this documentGuidance · reaffirm · $220M–$230M

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 18, 2026, 1:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PRE
Bullish
high confidence
Mentioned
$PRE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$PREBullishMed
01

Why it matters

The filing is a primary earnings release with quantified Q3 performance, cohort payback claims, and reaffirmed FY2026 and FY2027 revenue guidance, plus an updated second-half Adjusted EBITDA loss range.

02

Market read

Traders can update positioning around reaffirmed revenue targets, improving CAC and cash flow, and the quantified profitability drag expected in the second half.

03

What to watch

ARR is an annualized operating metric sensitive to billing timing and cancellations; investors may discount it versus IFRS revenue and scrutinize cohort retention beyond gross profit payback.

Relevance 7/10Novelty 8/10Timing: today’s earnings webcast at 8:30 a.m. ET

Background

Prenetics’ IM8 is positioned as an AI-native direct-to-consumer wellness brand, with cohort economics emphasized in the Q3 2026 release.

Company-level read

Ticker impact

$PREBullishHigh confidence
Context

Prenetics reported Q3 2026 revenue $64.1M (+228% YoY) and reaffirmed FY2026 revenue guidance $220–230M and FY2027 IM8 revenue guidance $400M+.

Expected impact

Likely upward bias as investors focus on record IM8 growth, CAC improvement, and positive adjusted free cash flow, tempered by the larger expected second-half EBITDA loss.

Evidence & confidence

The filing provides multiple decision-relevant datapoints: revenue above guidance, IM8 revenue above guidance, CAC declining, adjusted free cash flow turning positive, and a quantified second-half Adjusted EBITDA loss expectation of $30–35M.

Market effects

Reinforces investor appetite for direct-to-consumer wellness models that can show measurable customer payback and cohort economics.

Limited direct regional spillover; primarily affects US-listed consumer health and growth-stock sentiment.

Modest, as the story is company-specific but may influence global comps for subscription wellness and AI-native DTC brands.

Counterpoint

The company’s profitability remains negative, and the reaffirmed FY2027 ramp depends on continued customer retention and marketing efficiency; the second-half EBITDA loss widens to $30–35M.

Key entities

  • Prenetics Global Ltd

    Nasdaq-listed parent of IM8, reporting Q3 2026 results and reaffirming FY2026 and FY2027 guidance.

  • IM8

    Prenetics’ direct-to-consumer wellness brand whose revenue growth and customer cohort economics are central to the release.

  • General Catalyst Customer Value Fund

    Funding facility referenced for net fundings supporting positive adjusted free cash flow.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.